BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Grim-Stieger M, Keilani M, Mader RM, Marosi C, Schmidinger M, Zielinski CC, Fialka-Moser V, Crevenna R. Serum levels of tumour necrosis factor-alpha and interleukin-6 and their correlation with body mass index, weight loss, appetite and survival rate--preliminary data of Viennese outpatients with metastatic cancer during palliative chemotherapy. Eur J Cancer Care (Engl) 2008;17:454-62. [PMID: 18637115 DOI: 10.1111/j.1365-2354.2007.00874.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Loumaye A, Thissen JP. Biomarkers of cancer cachexia. Clin Biochem 2017;50:1281-8. [PMID: 28739222 DOI: 10.1016/j.clinbiochem.2017.07.011] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 9.2] [Reference Citation Analysis]
2 Sun W, Liu C, Zhang Y, Qiu X, Zhang L, Zhao H, Rong Y, Sun Y. Ilexgenin A, a novel pentacyclic triterpenoid extracted from Aquifoliaceae shows reduction of LPS-induced peritonitis in mice. European Journal of Pharmacology 2017;797:94-105. [DOI: 10.1016/j.ejphar.2017.01.019] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
3 Han J, Lu C, Meng Q, Halim A, Yean TJ, Wu G. Plasma concentration of interleukin-6 was upregulated in cancer cachexia patients and was positively correlated with plasma free fatty acid in female patients. Nutr Metab (Lond) 2019;16:80. [PMID: 31788012 DOI: 10.1186/s12986-019-0409-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
4 Jatoi A, Qi Y, Kendall G, Jiang R, McNallan S, Cunningham J, Mandrekar S, Yang P. The cancer anorexia/weight loss syndrome: exploring associations with single nucleotide polymorphisms (SNPs) of inflammatory cytokines in patients with non-small cell lung cancer. Support Care Cancer 2010;18:1299-304. [PMID: 20012999 DOI: 10.1007/s00520-009-0748-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
5 Ahmed DS, Isnard S, Lin J, Routy B, Routy JP. GDF15/GFRAL Pathway as a Metabolic Signature for Cachexia in Patients with Cancer. J Cancer 2021;12:1125-32. [PMID: 33442410 DOI: 10.7150/jca.50376] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Suh S, Choi YS, Yeom CH, Kwak SM, Yoon HM, Kim DG, Koh S, Park J, Lee MA, Lee YJ, Seo A, Ahn H, Yim E. Interleukin-6 but not tumour necrosis factor-alpha predicts survival in patients with advanced cancer. Support Care Cancer 2013;21:3071-7. [DOI: 10.1007/s00520-013-1878-4] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 3.3] [Reference Citation Analysis]
7 Schvartsman G, Gutierrez-Barrera AM, Song J, Ueno NT, Peterson SK, Arun B. Association between weight gain during adjuvant chemotherapy for early-stage breast cancer and survival outcomes. Cancer Med 2017;6:2515-22. [PMID: 29024537 DOI: 10.1002/cam4.1207] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
8 Lippitz BE, Harris RA. Cytokine patterns in cancer patients: A review of the correlation between interleukin 6 and prognosis. Oncoimmunology. 2016;5:e1093722. [PMID: 27467926 DOI: 10.1080/2162402x.2015.1093722] [Cited by in Crossref: 87] [Cited by in F6Publishing: 70] [Article Influence: 14.5] [Reference Citation Analysis]